Fannin Innovation Studio
Allterum is a spin-out company out of Fannin Innovation Studio. Fannin Innovation Studio is Houston’s most active early-stage life sciences development group with a primary focus on development of early stage assets, in partnership with our academic collaborators. The studio’s assets include therapeutics and medical devices, such as the in-house developed Brevitest point-of-care ELISA analyzer and in-licensed technologies from academic institutions including local Houstonian institutions such as MD Anderson Cancer Center, Baylor College of Medicine, Rice University, Houston Methodist, Texas A&M, Texas Children’s, University of Texas, and University of Houston. Fannin continues to play an active management role in Allterum Therapeutics.
Cancer Prevention and Research Institute of Texas (CPRIT)
Allterum received one of the first Product Development Seed Awards from Cancer Prevention and Research Institute of Texas (CPRIT), including over $2.92 million for preclinical development. CPRIT is a state agency that funds cancer research in Texas. Researchers and organizations in Texas are invited to apply for grants that match CPRIT’s mission and three goals to develop and advance innovation in the area of cancer for the prevention and cure of cancer.
Texas's Children's Hospital / Baylor College of Medicine
Dr. Eric Schafer, Assistant Professor in Pediatrics-Oncology, will be the Chair of Allterum’s Phase I clinical trial, which will include Texas Children’s Hospital as a site. TCH/BCM continues to be one of the premier pediatric hospitals in the nation, most recently tying for 3rd overall Best Children’s Hospital and #3 for pediatric cancer (U.S. News & World Report, 2019).
National Cancer Institute
Dr. Scott Durum and his group invented the 4A10 antibody technology and continue to provide scientific and technical advisement to the program. The National Cancer Institute (NCI) is the federal government’s principal agency for cancer research and training. Established under the National Cancer Institute Act of 1937, NCI is part of the National Institutes of Health (NIH), one of 11 agencies that make up the Department of Health and Human Services (HHS).
Children's Hospital of Philadelphia (CHOP)
Dr. Susan Rheingold, Medical Director of the Oncology Outpatient Clinic and Attending Physician at the Cancer Center of the Children’s Hospital of Philadelpha will be the Vice-Chair of Allterum’s Phase I clinical trial, which will include CHOP as a site.
The Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
Los Angeles, CA
Allterum will work with TACL to design, run, and manage its Phase I clinical trial. TACL is a leading organization for clinical trials in pediatric leukemia and lymphoma and brings vast clinical expertise to our program.
FUJIFILM Diosynth Biotechnologies
College Station, Texas
FUJIFILM Diosynth Biotechnologies is our manufacturing partner and is currently completing cGMP scale-up and manufacturing of the 4A10 drug in advance of our Phase I clinical trial.
Advancing an innovative solution for a critical and unmet medical need